An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies

Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur, Reena Philip

Research output: Contribution to journalReview articlepeer-review

Abstract

As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program.

Original languageEnglish (US)
Pages (from-to)1368-1372
Number of pages5
JournalClinical Cancer Research
Volume23
Issue number6
DOIs
StatePublished - Mar 15 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies'. Together they form a unique fingerprint.

Cite this